Crossmark

Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?

Published Online: 2023-10-07

Published Print: 2024-01

Authors

Roncato, Rossana

Puglisi, Fabio

Gerratana, Lorenzo https://orcid.org/0000-0002-8313-4834
License Information

Text and Data Mining valid from 2023-10-07

Version of Record valid from 2023-10-07
More Information

Article History

Received: 28 September 2023

Accepted: 29 September 2023

First Online: 7 October 2023

Declarations

:

: Conflicts of Interest and Source of Funding: FP has received honoraria from Amgen—Astrazeneca—Daiichi Sankyo—Celgene—Eisai—Eli Lilly-—Exact Sciences—Gilead—Ipsen—Menarini—MSD—Novartis—Pierre Fabre—Pfizer—Roche—Seagen—Takeda—Viatris. FP is currently receiving research grants from Astrazeneca, EISAI, and Roche. LG has received honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Incyte, Novartis, Pfizer, Menarini Stemmline, and AbbVie. LG is currently receiving research grants from Menarini Silicon Biosystems.

Document is current